HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Momoi, A. Articles by Takahara, J. Search for Related Content PubMed PubMed Citation Articles by Momoi, A. Articles by Takahara, J.

Inhibition of Monocyte Chemoattractant Protein-1 Expression in Cytokine-Treated Human Lung Epithelial Cells by Thiazolidinedione^*

^* From the First Department of Internal Medicine, Kagawa Medical University, Kita-gun, Kagawa, Japan.

Correspondence to: Koji Murao, MD, First Department of Internal Medicine, Kagawa Medical University, 1750–1, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan; e-mail:mkoji{at}kms.ac.jp

Study objective: Several lung diseases are characterized by the presence of increased numbers of activated macrophages. The recruitment and activation of peripheral blood monocytes are potentially critical regulatory events for the control of pulmonary inflammation. The chemokine monocyte chemoattractant protein (MCP)-1 is a potent chemoattractant for monocytes. MCP-1 is produced by lung epithelial cells during the course of inflammatory lung diseases. In the present study, we examined the effects of a thiazolidinedione (TZD), which is used to improve the insulin resistance of individuals with diabetes mellitus, on MCP-1 expression in a human lung epithelial cell line, A549.

Measurements and results: In A549 cells, interleukin (IL)-1ß and tumor necrosis factor (TNF)- induced endogenous MCP-1 protein secretion and messenger RNA expression. The TZD inhibited the increase of MCP-1 secretion by IL-1ß and TNF- treatment. The TZD inhibited the expression of MCP-1 messenger RNA with IL-1ß treatment, but not with TNF- treatment. This observation was confirmed by the results of a monocyte chemotactic assay. The transcriptional activity of human MCP-1 promoter in A549 cells paralleled the endogenous messenger RNA expression by cytokines and TZD treatment.

Conclusions: Our findings indicated that the suppression of the expression of MCP-1 could be accomplished by TZD treatment, raising the possibility that TZD may be of therapeutic value in several lung diseases in which MCP-1 plays an important role.

Key Words: A549 cell line • interleukin-1ß • monocyte chemoattractant protein-1 • thiazolidinedione • tumor necrosis factor-

This article has been cited by other articles:

				J. M. Bruun, A. S. Lihn, S. B. Pedersen, and B. Richelsen Monocyte Chemoattractant Protein-1 Release Is Higher in Visceral than Subcutaneous Human Adipose Tissue (AT): Implication of Macrophages Resident in the AT J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2282 - 2289. [Abstract] [Full Text] [PDF]

				Y.-M. Chen, W.-C. Chiang, S.-L. Lin, K.-D. Wu, T.-J. Tsai, and B.-S. Hsieh Dual Regulation of Tumor Necrosis Factor-{alpha}-Induced CCL2/Monocyte Chemoattractant Protein-1 Expression in Vascular Smooth Muscle Cells by Nuclear Factor-{kappa}B and Activator Protein-1: Modulation by Type III Phosphodiesterase Inhibition J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 978 - 986. [Abstract] [Full Text] [PDF]

				K.-i. Inoue, Y. Kawahito, and H. Sano Peroxisome Proliferator-Activated Receptor-{gamma} Expression in Lung Chest, July 1, 2002; 122(1): 386 - 387. [Full Text] [PDF]